No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Minimally Invasive Treatment Could Allow More Women to Conceive Without Fertility Treatments: Society for Interventional Radiology

Simple diagnostic procedure and treatment can provide clarity on infertility and hope for conception

Editor: What To Know

  • A simple diagnostic procedure, followed by an interventional radiology treatment known as fallopian tube recanalization, could allow a high percentage of women struggling with infertility from blocked fallopian tubes to conceive with less involved or, in some cases, no further invasive fertility procedures, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting.
  • Researchers at the University of British Columbia Hospital studied cases from 2015 to 2021 involving 956 women with infertility who previously had been diagnosed as having one or both fallopian tubes blocked based on the standard diagnostic procedure used to assess the openness of fallopian tubes, known as hysterosalpingogram (HSG).
  • And for many, it can actually give them the chance to conceive naturally,” said Lindsay Machan, MD, associate professor in the Department of Radiology at the University of British Columbia and a lead author of the study.

A simple diagnostic procedure, followed by an interventional radiology treatment known as fallopian tube recanalization, could allow a high percentage of women struggling with infertility from blocked fallopian tubes to conceive with less involved or, in some cases, no further invasive fertility procedures, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting. Researchers said that most women with with blocked fallopian tubes could have their condition easily corrected.

“This procedure and treatment can help women make an informed decision about infertility treatments. And for many, it can actually give them the chance to conceive naturally,” said Lindsay Machan, MD, associate professor in the Department of Radiology at the University of British Columbia and a lead author of the study. “As women increasingly desire more thorough discussions of available options and input into their medical care, they appreciate detailed information to help them make choices. This is especially true with fertility treatments.”

Researchers at the University of British Columbia Hospital studied cases from 2015 to 2021 involving 956 women with infertility who previously had been diagnosed as having one or both fallopian tubes blocked based on the standard diagnostic procedure used to assess the openness of fallopian tubes, known as hysterosalpingogram (HSG).  The women then underwent a selective salpingography to confirm their HSG diagnosis and, if needed, underwent fallopian tube recanalization. In many cases, researchers said, the purported blockage was only a piece of mucus that was easily removed.

The diagnostic examination known as selective salpingography showed that nearly one in four (23.8%) had been mistakenly told they had one or both blocked fallopian tubes.  Of those with a blockage, over half (56.7%) were unblocked using a fine wire in the fallopian recanalization process, researchers said. In sum, 80.5% of women in the study who had previously been told they had tubal blockages left the same day with both fallopian tubes open after a simple outpatient procedure. In an additional 15.9% a more precise diagnosis of significant tubal disease was made that in many cases, potentially altered treatment options.

Selective salpingography uses X-ray guidance to insert a tiny catheter through the cervix and into the opening of the fallopian tubes. A contrast dye is then injected to assess whether the tubes are open or blocked. The interventional radiologist, in many cases, is then able to perform recanalization which opens the tube using a fine guidewire. The procedure is performed as an outpatient under light sedation and typically takes under 30 minutes.

Machan said the research suggests that selective salpingography should be offered more broadly in assessing and treating female infertility. “Fertility treatments can be expensive and out of reach for many women,” he said. “Infertility is also an emotional, often heart-breaking journey, so having this diagnostic procedure and treatment available could be life-changing.”

Abstract 135: Radiologic Findings in Infertile Women Referred for Selective Salpingography and Fallopian Tube Recanalization. A. Sharma, A. Hadjivassiliou, L. Machan. Annual Scientific Meeting, June 11-16, 2022. This abstract can be found at sirmeeting.org after the embargo time.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy